Recordati to purchase EUSA Pharma
Upon deal completion, group will acquire company’s oncology product portfolio for $846 million
Recordati, an international pharma group that focuses on research, development, production and marketing of pharmaceutical products, has signed a share purchase agreement to acquire EUSA Pharma (UK) Ltd, a global specialty pharmaceutical company focused on rare and niche oncology diseases, for $846 million.
EUSA Pharma was founded in March 2015. Over the years, it has developed a portfolio of four products in that sector. The company has commercial operations in Europe, the Middle East and Africa (EMEA), along with the US, among other international markets.
The deal—which is expected to be finalized in the first half of 2022—would therefore offer Recordati that aforementioned portfolio, which is expected to contribute to 2023 revenue of over $169 million.
“We believe that the EUSA Pharma acquisition represents an excellent opportunity to further expand and reinforce our portfolio in a new and underserved therapeutic area, rare and niche oncology, with high potential growth products, and [it] will provide a platform for potential further future expansion in these areas,” says Andrea Recordati, chairman, Recordati.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
